DK3351539T3 - Krystallinsk monohydratkompleks af 1-cyan-2-(4-cyklopropyl-benzyl)-4-(beta-d-glucopyranos-1-yl)-benzen og prolin i krystalvand (1:1:1), fremgangsmåder til fremstilling deraf og dets anvendelse som SGLT-hæmmer - Google Patents
Krystallinsk monohydratkompleks af 1-cyan-2-(4-cyklopropyl-benzyl)-4-(beta-d-glucopyranos-1-yl)-benzen og prolin i krystalvand (1:1:1), fremgangsmåder til fremstilling deraf og dets anvendelse som SGLT-hæmmer Download PDFInfo
- Publication number
- DK3351539T3 DK3351539T3 DK18155079.9T DK18155079T DK3351539T3 DK 3351539 T3 DK3351539 T3 DK 3351539T3 DK 18155079 T DK18155079 T DK 18155079T DK 3351539 T3 DK3351539 T3 DK 3351539T3
- Authority
- DK
- Denmark
- Prior art keywords
- glucopyranos
- proline
- cyclopropyl
- cyano
- beta
- Prior art date
Links
- PESZPPAQWQMZAM-XNBWIAOKSA-N 2-[(4-cyclopropylphenyl)methyl]-4-[(2r,3r,4s,5s,6r)-2,3,4,5-tetrahydroxy-6-(hydroxymethyl)oxan-2-yl]benzonitrile Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@]1(O)C1=CC=C(C#N)C(CC=2C=CC(=CC=2)C2CC2)=C1 PESZPPAQWQMZAM-XNBWIAOKSA-N 0.000 title 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 title 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 title 1
- 239000013078 crystal Substances 0.000 title 1
- 150000004682 monohydrates Chemical class 0.000 title 1
- 229940121377 sodium-glucose co-transporter inhibitor Drugs 0.000 title 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
- C07H7/04—Carbocyclic radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Pyrane Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12177944 | 2012-07-26 | ||
| EP13740309.3A EP2877460B1 (en) | 2012-07-26 | 2013-07-25 | CRYSTALLINE COMPLEX OF 1-CYANO-2-(4-CYCLOPROPYL-BENZYL)-4-(ß-D-GLUCOPYRANOS-1-YL)-BENZENE, METHODS FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3351539T3 true DK3351539T3 (da) | 2023-01-30 |
Family
ID=48874313
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK18155079.9T DK3351539T3 (da) | 2012-07-26 | 2013-07-25 | Krystallinsk monohydratkompleks af 1-cyan-2-(4-cyklopropyl-benzyl)-4-(beta-d-glucopyranos-1-yl)-benzen og prolin i krystalvand (1:1:1), fremgangsmåder til fremstilling deraf og dets anvendelse som SGLT-hæmmer |
| DK13740309.3T DK2877460T3 (en) | 2012-07-26 | 2013-07-25 | CRYSTALLINE COMPLEX OF 1-CYANO-2-(4-CYCLOPROPYL-BENZYL)-4-(ß-D-GLUCOPYRANOS-1-YL)-BENZENE, METHODS FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK13740309.3T DK2877460T3 (en) | 2012-07-26 | 2013-07-25 | CRYSTALLINE COMPLEX OF 1-CYANO-2-(4-CYCLOPROPYL-BENZYL)-4-(ß-D-GLUCOPYRANOS-1-YL)-BENZENE, METHODS FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS. |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US9145434B2 (https=) |
| EP (3) | EP4166548A1 (https=) |
| JP (2) | JP6538556B2 (https=) |
| CN (2) | CN104470908A (https=) |
| AR (1) | AR091908A1 (https=) |
| AU (1) | AU2013294947B2 (https=) |
| BR (1) | BR112015001327B1 (https=) |
| CA (1) | CA2878698C (https=) |
| DK (2) | DK3351539T3 (https=) |
| EA (2) | EA025438B1 (https=) |
| ES (2) | ES2937665T3 (https=) |
| FI (1) | FI3351539T3 (https=) |
| HR (2) | HRP20181972T1 (https=) |
| HU (1) | HUE061450T2 (https=) |
| LT (1) | LT3351539T (https=) |
| MX (1) | MX357906B (https=) |
| PL (2) | PL3351539T3 (https=) |
| PT (2) | PT3351539T (https=) |
| RS (1) | RS63881B1 (https=) |
| SG (1) | SG11201500574QA (https=) |
| SI (2) | SI3351539T1 (https=) |
| TW (1) | TW201418275A (https=) |
| WO (1) | WO2014016381A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9145434B2 (en) | 2012-07-26 | 2015-09-29 | Boehringer Ingelheim International Gmbh | Crystalline complex of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(ss-d-glucopyranos-1-yl)-benzene, methods for its preparation and the use thereof for preparing medicaments |
| PT2981269T (pt) | 2013-04-04 | 2023-10-10 | Boehringer Ingelheim Vetmedica Gmbh | Tratamento de distúrbios metabólicos em animais equinos |
| ES2969764T3 (es) * | 2013-12-17 | 2024-05-22 | Boehringer Ingelheim Vetmedica Gmbh | Un inhibidor de SGLT-2 para usar en el tratamiento de un trastorno metabólico en animales felinos |
| CN115671290A (zh) | 2014-01-23 | 2023-02-03 | 勃林格殷格翰动物保健有限公司 | 犬科动物中代谢紊乱的治疗 |
| WO2015150299A2 (en) | 2014-04-01 | 2015-10-08 | Boehringer Ingelheim Vetmedica Gmbh | Treatment of metabolic disorders in equine animals |
| CN103965020B (zh) * | 2014-05-06 | 2015-09-09 | 启东东岳药业有限公司 | 制备5-碘-2-溴苄醇的方法 |
| WO2016046150A1 (en) * | 2014-09-25 | 2016-03-31 | Boehringer Ingelheim Vetmedica Gmbh | Combination treatment of sglt2 inhibitors and dopamine agonists for preventing metabolic disorders in equine animals |
| HUE052588T2 (hu) * | 2014-09-30 | 2021-05-28 | Jiangsu Hengrui Medicine Co | Az L-prolin/nátrium-glukóz kotranszporter 2 gátló kristály komplexének kristálya |
| CZ2015110A3 (cs) * | 2015-02-18 | 2016-08-31 | Zentiva, K.S. | Pevné formy empagliflozinu |
| KR102659761B1 (ko) | 2015-08-27 | 2024-04-24 | 베링거잉겔하임베트메디카게엠베하 | Sglt-2 억제제를 포함하는 액상 약제학적 조성물 |
| WO2017203457A1 (en) * | 2016-05-26 | 2017-11-30 | Dr. Reddy's Laboratories Limited | Solid state forms of empagliflozin |
| KR102226465B1 (ko) | 2016-05-28 | 2021-03-11 | 하이난 수안주 파마 코포레이션 리미티드 | 나트륨-글루코스 공수송체 2에 대한 억제제의 결정형 |
| US11225500B2 (en) | 2017-12-19 | 2022-01-18 | Boehringer Ingelheim Vetmedica Gmbh | Synthesis of 1:1:1 co-crystal of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(β-D-glucopyranos-1-yl)-benzene, L-proline and water |
| EP4064854A1 (en) | 2019-11-28 | 2022-10-05 | Boehringer Ingelheim Vetmedica GmbH | Use of sglt-2 inhibitors in the drying-off of non-human mammals |
| AU2021222297B2 (en) | 2020-02-17 | 2026-01-22 | Boehringer Ingelheim Vetmedica Gmbh | Use of SGLT-2 inhibitors for the prevention and/or treatment of cardiac diseases in felines |
| JP2024525981A (ja) | 2021-07-28 | 2024-07-12 | ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー | ヒト以外の哺乳動物における腎疾患の予防及び／又は治療のためのｓｇｌｔ－２阻害剤の使用 |
| JP2024527434A (ja) | 2021-07-28 | 2024-07-24 | ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー | ネコ科動物を除く非ヒト哺乳動物、特にイヌ科動物における心臓疾患の予防及び／又は治療のためのｓｇｌｔ－２阻害剤の使用 |
| US20240269105A1 (en) | 2021-07-28 | 2024-08-15 | Boehringer Ingelheim Vetmedica Gmbh | Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals |
| AU2023277704A1 (en) | 2022-05-25 | 2024-12-05 | Boehringer Ingelheim Vetmedica Gmbh | Aqueous pharmaceutical compositions comprising sglt-2 inhibitors |
| EP4676494A1 (en) | 2023-03-06 | 2026-01-14 | Boehringer Ingelheim Vetmedica GmbH | Systems for delivery of liquid pharmaceutical compositions in particular comprising one or more sglt-2 inhibitor(s) |
| WO2024223388A1 (en) | 2023-04-24 | 2024-10-31 | Boehringer Ingelheim Vetmedica Gmbh | Crystalline complexes between velagliflozin and selected co-crystal forming agents, methods for their preparation and the use thereof for preparing medicaments |
| KR20260019532A (ko) | 2023-05-24 | 2026-02-10 | 베링거잉겔하임베트메디카게엠베하 | 하나 이상의 sglt-2 억제제와 텔미사르탄을 포함하는 비인간 포유류의 신장 질환 및/또는 고혈압의 병용 치료 및/또는 예방 |
| US20240390317A1 (en) | 2023-05-24 | 2024-11-28 | Boehringer Ingelheim Vetmedica Gmbh | Combination treatment and/or prevention of cardiac diseases in non-human mammals comprising one or more sglt-2 inhibitors and pimobendan and/or telmisartan |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002254567B2 (en) * | 2001-04-11 | 2007-10-11 | Bristol-Myers Squibb Company | Amino acid complexes of C-aryl glucosides for treatment of diabetes and method |
| US7927613B2 (en) * | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
| JP2006516257A (ja) * | 2003-01-03 | 2006-06-29 | ブリストル−マイヤーズ スクイブ カンパニー | Ｃ−アリールグルコシドｓｇｌｔ２阻害剤の製造法 |
| CN103030617A (zh) * | 2004-03-16 | 2013-04-10 | 贝林格尔.英格海姆国际有限公司 | 吡喃葡萄糖基取代的苯基衍生物、含该化合物的药物、其用途及其制造方法 |
| AU2006289093A1 (en) * | 2005-09-08 | 2007-03-15 | Boehringer Ingelheim International Gmbh | Crystalline forms of 1-chloro-4-(beta-D-glucopyranos-1-yl)-2-(4-ethynyl-benzyl)-benzene, methods for its preparation and the use thereof for preparing medicaments |
| AR059489A1 (es) * | 2006-02-15 | 2008-04-09 | Boehringer Ingelheim Vetmed | Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion |
| TWI370818B (en) * | 2006-04-05 | 2012-08-21 | Astellas Pharma Inc | Cocrystal of c-glycoside derivative and l-proline |
| PE20080697A1 (es) | 2006-05-03 | 2008-08-05 | Boehringer Ingelheim Int | Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion |
| US7919598B2 (en) | 2006-06-28 | 2011-04-05 | Bristol-Myers Squibb Company | Crystal structures of SGLT2 inhibitors and processes for preparing same |
| TW200817424A (en) | 2006-08-04 | 2008-04-16 | Daiichi Sankyo Co Ltd | Benzylphenyl glucopyranoside derivatives |
| TW200904405A (en) | 2007-03-22 | 2009-02-01 | Bristol Myers Squibb Co | Pharmaceutical formulations containing an SGLT2 inhibitor |
| US20080287529A1 (en) * | 2007-05-18 | 2008-11-20 | Bristol-Myers Squibb Company | Crystal structures of sglt2 inhibitors and processes for preparing same |
| CN101468976B (zh) * | 2007-12-27 | 2013-11-20 | 百时美施贵宝公司 | Sglt2抑制剂的晶体结构及其制备方法 |
| CN103910702A (zh) * | 2008-08-22 | 2014-07-09 | 泰拉科斯有限公司 | 制备sglt2抑制剂的方法 |
| AU2009286380B2 (en) | 2008-08-28 | 2011-09-15 | Pfizer Inc. | Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives |
| WO2010048358A2 (en) | 2008-10-22 | 2010-04-29 | Auspex Pharmaceutical, Inc. | Ethoxyphenylmethyl inhibitors of sglt2 |
| WO2011153712A1 (en) * | 2010-06-12 | 2011-12-15 | Theracos, Inc. | Crystalline form of benzylbenzene sglt2 inhibitor |
| US9145434B2 (en) | 2012-07-26 | 2015-09-29 | Boehringer Ingelheim International Gmbh | Crystalline complex of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(ss-d-glucopyranos-1-yl)-benzene, methods for its preparation and the use thereof for preparing medicaments |
| PT2981269T (pt) | 2013-04-04 | 2023-10-10 | Boehringer Ingelheim Vetmedica Gmbh | Tratamento de distúrbios metabólicos em animais equinos |
-
2013
- 2013-07-23 US US13/948,751 patent/US9145434B2/en active Active
- 2013-07-25 EA EA201500038A patent/EA025438B1/ru not_active IP Right Cessation
- 2013-07-25 EP EP22202153.7A patent/EP4166548A1/en active Pending
- 2013-07-25 AR ARP130102660A patent/AR091908A1/es unknown
- 2013-07-25 EP EP13740309.3A patent/EP2877460B1/en active Active
- 2013-07-25 ES ES18155079T patent/ES2937665T3/es active Active
- 2013-07-25 CA CA2878698A patent/CA2878698C/en active Active
- 2013-07-25 PL PL18155079.9T patent/PL3351539T3/pl unknown
- 2013-07-25 SI SI201332031T patent/SI3351539T1/sl unknown
- 2013-07-25 HR HRP20181972TT patent/HRP20181972T1/hr unknown
- 2013-07-25 CN CN201380037186.1A patent/CN104470908A/zh active Pending
- 2013-07-25 AU AU2013294947A patent/AU2013294947B2/en active Active
- 2013-07-25 JP JP2015523552A patent/JP6538556B2/ja active Active
- 2013-07-25 TW TW102126724A patent/TW201418275A/zh unknown
- 2013-07-25 MX MX2015000962A patent/MX357906B/es active IP Right Grant
- 2013-07-25 WO PCT/EP2013/065736 patent/WO2014016381A1/en not_active Ceased
- 2013-07-25 RS RS20230025A patent/RS63881B1/sr unknown
- 2013-07-25 PT PT181550799T patent/PT3351539T/pt unknown
- 2013-07-25 SI SI201331237T patent/SI2877460T1/sl unknown
- 2013-07-25 EP EP18155079.9A patent/EP3351539B1/en active Active
- 2013-07-25 HR HRP20230081TT patent/HRP20230081T1/hr unknown
- 2013-07-25 PT PT13740309T patent/PT2877460T/pt unknown
- 2013-07-25 DK DK18155079.9T patent/DK3351539T3/da active
- 2013-07-25 CN CN201810468431.9A patent/CN108774200A/zh active Pending
- 2013-07-25 ES ES13740309.3T patent/ES2694675T3/es active Active
- 2013-07-25 BR BR112015001327-9A patent/BR112015001327B1/pt active IP Right Grant
- 2013-07-25 SG SG11201500574QA patent/SG11201500574QA/en unknown
- 2013-07-25 PL PL13740309T patent/PL2877460T3/pl unknown
- 2013-07-25 EA EA201600506A patent/EA201600506A1/ru unknown
- 2013-07-25 LT LTEP18155079.9T patent/LT3351539T/lt unknown
- 2013-07-25 HU HUE18155079A patent/HUE061450T2/hu unknown
- 2013-07-25 DK DK13740309.3T patent/DK2877460T3/en active
-
2018
- 2018-05-08 JP JP2018089968A patent/JP2018135384A/ja active Pending
-
2022
- 2022-07-25 FI FIEP18155079.9T patent/FI3351539T3/fi active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3351539T3 (da) | Krystallinsk monohydratkompleks af 1-cyan-2-(4-cyklopropyl-benzyl)-4-(beta-d-glucopyranos-1-yl)-benzen og prolin i krystalvand (1:1:1), fremgangsmåder til fremstilling deraf og dets anvendelse som SGLT-hæmmer | |
| NO2020024I1 (no) | Kombinasjon av relebaktam, eventuelt i form av monohydrat, imipenem og cilastatin, eventuelt i form av natriumsalt | |
| DK2455374T3 (da) | Fremgangsmåde til fremstillingen af forbindelser der kan anvendes som inhibitorer af SGLT | |
| DK2751102T3 (da) | Forbindelser og sammensætninger som C-kit-kinasehæmmere | |
| NO2018019I1 (no) | Ertugliflozin, eventuelt som en krystallform, særlig som en ko-krystall med L-pyroglutaminsyre, og spesielt som Ertugliflozin L-pyroglutaminsyre | |
| CL2014001628A1 (es) | Metodos para purificar glicosidos de ateviol; composiciones y usos de los mismos | |
| DK2814504T3 (da) | Protease inhibitor indeholdende sammensætninger, sammensætninger omfattende samme og metoder til fremstilling og brug af samme | |
| DK2920149T3 (da) | 3-aminocycloalkyl-forbindelser som ror-gamma-t-inhibitorer og anvendelser deraf | |
| CL2012002737A1 (es) | Anticuerpo anti-cd40 humanizado; polinucleótido que lo codifica; composición farmacéutica que comprende dicho anticuerpo; y su uso para bloquear una respuesta inmunitaria mediada por cd40 humana. | |
| ZA201404273B (en) | 2',4'-diflouro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication | |
| DK2877574T3 (da) | Alpha (1,2)-fucosyltransferaser egnet til anvendelse i fremstillingen af fucosylerede oligosaccharider | |
| EP3110901A4 (en) | Use of r-1233 in liquid chillers | |
| DK3141542T3 (da) | Substituerede benzaldehydforbindelser og fremgangsmåder til anvendelse deraf ved øgning af vævsiltning | |
| CL2014002903A1 (es) | Composición geopolimérica de aluminosilicato; método de preparacion y sus usos. | |
| DK2857401T3 (da) | Hidtil ukendt -lactamaseinhibitor og fremgangsmåde til at fremstille samme | |
| CO6801796A2 (es) | Composiciones de tratamiento de pozo de liberación retardada para uso en fluídos de tratamiento de pozo | |
| DK3269386T3 (da) | Aluminiumforbindelser til anvendelse inden for behandling og i vacciner | |
| DK3424920T3 (da) | Co-krystaller af (s)-n-methyl-8-(1-((2'-methyl-[4,5'-bipyrimidin]-6-yl)amino)propan-2-yl)quinolin-4-carboxamid og deuterede derivater deraf som dna-pk-inhibitorer | |
| HRP20181695T1 (hr) | Kristalni oblik inhibitora benzilbenzena sglt2 | |
| PT2798398T (pt) | Vidraça multipla para difusão variável por cristais líquidos | |
| DK2683371T3 (da) | Forbindelser og fremgangsmåder til forbedring af forringet endogen fibrinolyse ved anvendelse af histondeacetylasehæmmere | |
| DK2736888T3 (da) | 3-heteroaroylaminopropionsyrederivater og deres anvendelse som farmaceutika | |
| DK2665793T3 (da) | Azeotroplignende sammensætninger af trans-1,1,1,4,4,4-hexafluor-2-buten og vand | |
| PT2739621T (pt) | Cristais do composto 2-acilaminotiazol | |
| DK1994005T3 (da) | Tetrahydronaphthalinderivater, fremgangsmåde til fremstilling heraf og anvendelse heraf som betændelseshæmmere |